港股异动 | 艾美疫苗(06660)放量涨超18% 领涨医药板块及港股通标的 公司多款大单品上市在即

智通财经
23 Oct 2024

智通财经APP获悉,艾美疫苗(06660)早盘放量走高,盘中涨超18%,领涨医药板块及港股通标的。截至发稿,涨9.07%,报8.31港元,成交额1.24亿港元。

消息面上,艾美疫苗近期公布,公司在研迭代无血清狂苗Ⅲ期临床试验数据已完成揭盲及统计分析工作,结果显示该疫苗具有良好的免疫原性和安全性,达到临床预设目标。集团指,已建设完成具备生产能力的无血清迭代狂犬病疫苗生产车间。截至目前,全球市场上尚未有无血清狂犬病疫苗获批上市,该产品有望成为首个上市产品。

值得注意的是,截至2024年上半年末,公司三款重磅大单品13价肺炎结合疫苗、无血清迭代狂犬病疫苗及23价肺炎多糖疫苗进入上市冲刺阶段。此外,公司的两款重磅大单品mRNA RSV (呼吸道合胞病毒)疫苗与mRNA带状疱疹疫苗已向中美两国提交临床试验申请。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10